Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-06-28
2000-08-29
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3144
Patent
active
061109274
ABSTRACT:
A method of treating atrial fibrillation in mammals using loratadine.
REFERENCES:
patent: 4282233 (1981-08-01), Vilani
patent: 4371516 (1983-02-01), Gregory et al.
patent: 4659716 (1987-04-01), Villani et al.
Mays et al., J. Clin. Invest., 96:282-92 (1995).
Radwanski et al., J. Clin. Pharmacol., 27:530-33 (1987).
Hey et al., Clin. Exp. Allergy, 25:974-84 (1995).
Luck et al., J. Allergy Clin. Immunol. (Abstract), 282:568 (1995).
[author?], Am. J. Cardiol., 74:208 (1994).
Delpon et al., Cardiovasc. Res., 35:341-50 (1997).
Haria et al., Drugs, 48(4):617-37 (1994).
Buckland Guy
Friedrich Tilman
Satler Carol A.
Benson Gregg C.
Henley III Raymond
Pfizer Inc
Raymer Gregory P.
Richardson Peter C.
LandOfFree
Loratadine for use as an antiarrhythmic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Loratadine for use as an antiarrhythmic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Loratadine for use as an antiarrhythmic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1250148